PHARMACOVIGILANCE (PV) WORKSHOP *for Pharmaceutical Companies*

Photo Session with all Participants : PV Workshop event in Semarang

Introduction

In order to strengthen post-market supervision, PV workshops for the pharmaceutical companies were held in Semarang (26th-27th of February 2020) and Jakarta (11th-12th of March 2020). The workshops were carried out as an effort to equate perceptions, improve understanding and competence of the pharmaceutical industry in pharmacovigilance. They were expected to strengthen the safety and quality assurance of drugs by the pharmaceutical industry.

Key Players

Approximately 200 participants and 15 key players of PV system and regulators from Badan POM, and Pharmaceutical companies participated in the workshops.

Speakers

These workshops were attended by representative of JICA Mr. Yoshihiko Sano for both event in Jakarta & Semarang, and Head of Badan POM Dr. Ir. Penny K. Lukito, MCP., for event in Semarang. Also invited some experts, they are: Ms. Yuka Nozaka from Pharmaceuticals and Medical Devices Agency (PMDA) Japan, Dra. Rita Endang, Apt., M.Kes., Dra. Tri Asti Isnariani, Apt, M.Pharm and Dra. Nurma Hidayati, Apt., M.Epid. from Badan POM, Destita Khairilisani, S.Farm., Apt. as a representative of Japan Pharmaceutical Manufacturers Association (JPMA), >> (next)

dr. Febria Rehinatha, from PT AstraZeneca Indonesia, Dra. Sally Lelolita, Apt., M.Kes., from PT Bayer Indonesia, and Christiyanti Dewi, S.Farm., Apt. from PT Merck Sharp Dohme Pharma Tbk.,

Discussion between participants : PV Workshop in Jakarta

Discussions

The active discussions between participants separated by 6-8 persons per each discussion group were facilitated by Badan POM officers, all speakers and facilitators from pharmaceutical companies including Dwi Nofiarny, S.Si., Apt., M.Sc from PT Dexa Medica, Fachria Evi Yanthi, Apt from PT Pfizer Indonesia, and Nastia Hidayati, S.Si., M.Far., Apt from PT Kimia Farma Tbk. The application and reporting of adverse drug reactions was mandatory for pharmaceutical companies in Indonesia. In terms of monitoring of pharmacovigilance reports, the foreign investment (PMA) pharmaceutical companies had more established maturity level than the Domestic Investment (PMDN) ones. Apart from the quality of the reporting which also needed to be maintained, the compliance of the PV system implementation must be still identified and monitored. These workshops were supposed to increase understanding and competence of pharmaceutical companies to implement better pharmacovigilance activities.